Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials

European Journal of Cancer

Volumn 51, Issue 13, 2015, Pages 1704-1713

  Peeters, M ^a   Kafatos, G ^b   Taylor, A ^b   Gastanaga, V M ^c   Oliner, K S ^c   Hechmati, G ^c   Terwey, J H ^c   Van Krieken, J H ^d  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b AMGEN LTD   (United Kingdom)

^c AMGEN INC   (United States)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BRAF; KRAS; mCRC; NRAS; Panitumumab; RAS prevalence

Indexed keywords

BEVACIZUMAB; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NRAS PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; NEXT GENERATION SEQUENCING; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; PATIENT CODING; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; ADOLESCENT; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; EXON; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; METASTASIS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GTP PHOSPHOHYDROLASES; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM METASTASIS; PATIENT SELECTION; PHENOTYPE; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84938748933     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.05.017     Document Type: Article

References (29)

1. R.G. Amado, M. Wolf, M. Peeters, E. Van Cutsem, S. Siena, D.J. Freeman, and et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 2008 1626 1634
2. D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, and et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
3. J.Y. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. Burkes, M. Barugel, and et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 2010 4697 4705
4. D.J. Jonker, C.J. O'Callaghan, C.S. Karapetis, J.R. Zalcberg, D. Tu, H.J. Au, and et al. Cetuximab for the treatment of colorectal cancer N Engl J Med 357 2007 2040 2048
5. M. Peeters, T.J. Price, A. Cervantes, A.F. Sobrero, M. Ducreux, Y. Hotko, and et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer J Clin Oncol 28 2010 4706 4713
6. A.F. Sobrero, J. Maurel, L. Fehrenbacher, W. Scheithauer, Y.A. Abubakr, M.P. Lutz, and et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer J Clin Oncol 26 2008 2311 2319
7. E. Van Cutsem, M. Peeters, S. Siena, Y. Humblet, A. Hendlisz, B. Neyns, and et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 2007 1658 1664
8. E. Van Cutsem, C.H. Köhne, E. Hitre, J. Zaluski, C.R. Chang Chien, A. Makhson, and et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
9. M. Peeters, J.Y. Douillard, E. Van Cutsem, S. Siena, K. Zhang, R. Williams, and et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab J Clin Oncol 31 2013 759 765
10. W. De Roock, V. De Vriendt, N. Normanno, F. Ciardiello, and S. Tejpar KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer Lancet Oncol 12 2011 594 603
11. M. Peeters, K.S. Oliner, A. Parker, S. Siena, E. Van Cutsem, J. Huang, and et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer Clin Cancer Res 19 2013 1902 1912
12. J.-Y. Douillard, K.S. Oliner, S. Siena, J. Tabernero, R. Burkes, M. Barugel, and et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N Engl J Med 369 2013 1023 1034
13. C. Bokemeyer, C.H. Köhne, F. Ciardiello, H.J. Lenz, V. Heinemann, U. Klinkhardt, and et al. Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab J Clin Oncol 32 Suppl 2014 Abstract 3505
14. F. Ciardiello, H.J. Lenz, C.H. Köhne, V. Heinemann, S. Tejpar, I. Melezinek, and et al. Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab J Clin Oncol 32 Suppl 2014 Abstract 3506
15. L.S. Schwartzberg, F. Rivera, M. Karthaus, G. Fasola, J.L. Canon, J.R. Hecht, and et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer J Clin Oncol 32 2014 2240 2247
16. M. Karthaus, R. Hofheinz, L. Mineur, R. Greil, J. Thaler, E. Fernebro, and et al. Impact of tumour RAS/BRAF status on efficacy of first-line panitumumab + FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) Ann Oncol Suppl 2014 Abstract 5672 (5672P)
17. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: colon cancer. V1; 2015. < http://www.nccn.org/professionals/physician-gls/PDF/colon.pdf >.
18. E. Van Cutsem, A. Cervantes, B. Nordlinger, and D. Arnold Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 25 2014 iii1 iii9
19. A. Lievre, J.B. Bachet, V. Boige, A. Cayre, D. Le Corre, E. Buc, and et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Clin Oncol 26 2008 374 379
20. C.S. Karapetis, S. Khambata-Ford, D.J. Jonker, C.J. O'Callaghan, D. Tu, N.C. Tebbutt, and et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 2008 1757 1765
21. M. Peeters, K.S. Oliner, T.J. Price, A. Cervantes, A.F. Sobrero, M. Ducreux, and et al. Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) + FOLFIRI for 2nd-line treatment (tx) of metastatic colorectal cancer (mCRC) J Clin Oncol 32 Suppl 2014 Abstract 3568
22. S. Stintzing, A. Jung, L. Rossius, D.P. Modest, L.F. von Weikersthal, T. Decker, and et al. Mutations within the EGFR signaling pathway: Influences on efficacy in FIRE-3 - a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients J Clin Oncol 32 Suppl 3 2014 Abstract 445
23. C.P. Vaughn, S.D. Zobell, L.V. Furtado, C.L. Baker, and W.S. Samowitz Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer Genes Chromosomes Cancer 50 2011 307 312
24. C. Bokemeyer, E. Van Cutsem, P. Rougier, F. Ciardiello, S. Heeger, M. Schlichting, and et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials Eur J Cancer 48 2012 1466 1475
25. V. Morris, M.J. Overman, Z.Q. Jiang, C. Garrett, S. Agarwal, C. Eng, and et al. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer Clin Colorectal Cancer 13 2014 164 171
26. R. Yaeger, A. Cercek, J.F. Chou, B.E. Sylvester, N.E. Kemeny, J.F. Hechtman, and et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer Cancer 120 2014 2316 2324
27. T. Brodowicz, D. Vrbanec, K. Kaczirek, T.E. Ciuleanu, R. Knittelfelder, E. Lindner, and et al. FOLFOX4 plus cetuximab administered weekly or every two weeks in first-line treatment of patients with KRAS and NRAS wild-type (wt) metastatic colorectal cancer (mCRC) J Clin Oncol 32 2014 Abstract LBA391
28. E. Van Cutsem, C. Eng, E. Nowara, A. Swieboda-Sadlej, N.C. Tebbutt, E. Mitchell, and et al. Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer Clin Cancer Res 20 2014 4240 4250
29. U. Malapelle, C. Bellevicine, M. Salatiello, C. de Luca, E. Rispo, P. Riccio, and et al. Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective J Clin Pathol 65 2012 940 944